Christian Lunetta

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4687995/publications.pdf

Version: 2024-02-01

125 papers	9,675 citations	101384 36 h-index	40881 93 g-index
129 all docs	129 docs citations	129 times ranked	10398 citing authors

#	Article	IF	Citations
1	A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD. Neuron, 2011, 72, 257-268.	3.8	3,833
2	Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurology, The, 2012, 11, 323-330.	4.9	1,039
3	Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. Neuron, 2018, 97, 1268-1283.e6.	3.8	517
4	Mutations in the Matrin 3 gene cause familial amyotrophic lateral sclerosis. Nature Neuroscience, 2014, 17, 664-666.	7.1	398
5	Clinical characteristics of patients with familial amyotrophic lateral sclerosis carrying the pathogenic GGGGCC hexanucleotide repeat expansion of C9ORF72. Brain, 2012, 135, 784-793.	3.7	182
6	Longâ€term survival in amyotrophic lateral sclerosis: A populationâ€based study. Annals of Neurology, 2014, 75, 287-297.	2.8	141
7	Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 5-14.	1.1	133
8	Amyotrophic Lateral Sclerosis Multiprotein Biomarkers in Peripheral Blood Mononuclear Cells. PLoS ONE, 2011, 6, e25545.	1.1	123
9	Burden, depression, and anxiety in caregivers of people with amyotrophic lateral sclerosis. Psychology, Health and Medicine, 2010, 15, 685-693.	1.3	106
10	Genetic counselling in ALS: facts, uncertainties and clinical suggestions. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 478-485.	0.9	99
11	Serum C-Reactive Protein as a Prognostic Biomarker in Amyotrophic Lateral Sclerosis. JAMA Neurology, 2017, 74, 660.	4.5	96
12	Factors predicting survival in ALS: a multicenter Italian study. Journal of Neurology, 2017, 264, 54-63.	1.8	96
13	Clinical exome sequencing in earlyâ€onset generalized dystonia and largeâ€scale resequencing followâ€up. Movement Disorders, 2017, 32, 549-559.	2.2	94
14	Emotional empathy in amyotrophic lateral sclerosis: a behavioural and voxel-based morphometry study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2014, 15, 21-29.	1.1	85
15	Structural brain correlates of cognitive and behavioral impairment in <scp>MND</scp>. Human Brain Mapping, 2016, 37, 1614-1626.	1.9	84
16	Physical activity and amyotrophic lateral sclerosis: A European populationâ€based caseâ€“control study. Annals of Neurology, 2014, 75, 708-716.	2.8	79
17	C9ORF72 hexanucleotide repeat expansions in the Italian sporadic ALS population. Neurobiology of Aging, 2012, 33, 1848.e15-1848.e20.	1.5	76
18	Microstructural white matter correlates of emotion recognition impairment in Amyotrophic Lateral Sclerosis. Cortex, 2014, 53, 1-8.	1.1	71

#	Article	IF	Citations
19	Polymeric biomaterials for 3D printing in medicine: An overview. Annals of 3D Printed Medicine, 2021, 2, 100011.	1.6	71
20	Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 397-405.	1.1	68
21	Recent advances in amyotrophic lateral sclerosis. Journal of Neurology, 2016, 263, 1241-1254.	1.8	67
22	Strictly monitored exercise programs reduce motor deterioration in ALS: preliminary results of a randomized controlled trial. Journal of Neurology, 2016, 263, 52-60.	1.8	67
23	Trauma and amyotrophic lateral sclerosis: a caseâ€“control study from a populationâ€based registry. European Journal of Neurology, 2012, 19, 1509-1517.	1.7	63
24	T helper-17 activation dominates the immunologic milieu of both amyotrophic lateral sclerosis and progressive multiple sclerosis. Clinical Immunology, 2013, 148, 79-88.	1.4	56
25	Existential well-being and spirituality of individuals with amyotrophic lateral sclerosis is related to psychological well-being of their caregivers. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2011, 12, 105-108.	2.3	55
26	Whole-blood global DNA methylation is increased in amyotrophic lateral sclerosis independently of age of onset. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2014, 15, 98-105.	1.1	54
27	Structural and functional brain signatures of C9orf72 in motor neuron disease. Neurobiology of Aging, 2017, 57, 206-219.	1.5	54
28	Mitochondrial DNA copy number and D-loop region methylation in carriers of amyotrophic lateral sclerosis gene mutations. Epigenomics, 2018, 10, 1431-1443.	1.0	50
29	The serum level of free testosterone is reduced in amyotrophic lateral sclerosis. Journal of the Neurological Sciences, 2002, 195, 67-70.	0.3	48
30	The Cognitive and Behavioural Profile of Amyotrophic Lateral Sclerosis: Application of the Consensus Criteria. Behavioural Neurology, 2013, 27, 143-153.	1.1	44
31	CHCH10 mutations in an Italian cohort of familial and sporadic amyotrophic lateral sclerosis patients. Neurobiology of Aging, 2015, 36, 1767.e3-1767.e6.	1.5	44
32	Impaired expression of insulinâ€like growth factorâ€1 system in skeletal muscle of amyotrophic lateral sclerosis patients. Muscle and Nerve, 2012, 45, 200-208.	1.0	43
33	Pain in Amyotrophic Lateral Sclerosis: a psychological perspective. Neurological Sciences, 2012, 33, 1193-1196.	0.9	42
34	The MITOS system predicts long-term survival in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 1180-1185.	0.9	42
35	Peptidylprolyl isomerase A governs TARDBP function and assembly in heterogeneous nuclear ribonucleoprotein complexes. Brain, 2015, 138, 974-991.	3.7	40
36	TBK1 is associated with ALS and ALS-FTD in Sardinian patients. Neurobiology of Aging, 2016, 43, 180.e1-180.e5.	1.5	40

#	Article	IF	Citations
37	Wide phenotypic spectrum of the TARDBP gene: homozygosity of A382T mutation in a patient presenting with amyotrophic lateral sclerosis, Parkinson's disease, and frontotemporal lobar degeneration, and in neurologically healthy subject. Neurobiology of Aging, 2012, 33, 1846.e1-1846.e4.	1.5	38
38	TBK1mutations in Italian patients with amyotrophic lateral sclerosis: genetic and functional characterisation. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 869-875.	0.9	38
39	The Italian multicenter experience with edaravone in amyotrophic lateral sclerosis. Journal of Neurology, 2020, 267, 3258-3267.	1.8	37
40	Comparative Analysis of C9orf72 and Sporadic Disease in a Large Multicenter ALS Population: The Effect of Male Sex on Survival of C9orf72 Positive Patients. Frontiers in Neuroscience, 2019, 13, 485.	1.4	35
41	Increase in DNA methylation in patients with amyotrophic lateral sclerosis carriers of not fully penetrant SOD1 mutations. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 93-101.	1.1	34
42	The unfolded protein response in amyotrophic later sclerosis: results of a phase 2 trial. Brain, 2021, 144, 2635-2647.	3.7	33
43	Erythropoietin in amyotrophic lateral sclerosis: a multicentre, randomised, double blind, placebo controlled, phase III study. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 879-886.	0.9	32
44	Brain MR Imaging in Patients with Lower Motor Neuronâ€“Predominant Disease. Radiology, 2016, 280, 545-556.	3.6	32
45	Focus on the heterogeneity of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 485-495.	1.1	32
46	Exploring motor and visual imagery in Amyotrophic Lateral Sclerosis. Experimental Brain Research, 2013, 226, 537-547.	0.7	31
47	miR-129-5p: A key factor and therapeutic target in amyotrophic lateral sclerosis. Progress in Neurobiology, 2020, 190, 101803.	2.8	31
48	Decreased Levels of Foldase and Chaperone Proteins Are Associated with an Early-Onset Amyotrophic Lateral Sclerosis. Frontiers in Molecular Neuroscience, 2017, 10, 99.	1.4	30
49	Mutation in the senataxin gene found in a patient affected by familial ALS with juvenile onset and slow progression. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2011, 12, 228-230.	2.3	28
50	The Peripheral Nervous System in Amyotrophic Lateral Sclerosis: Opportunities for Translational Research. Frontiers in Neuroscience, 2019, 13, 601.	1.4	28
51	Extrapyramidal and cognitive signs in amyotrophic lateral sclerosis: A population based cross-sectional study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16, 324-330.	1.1	26
52	Trauma and amyotrophic lateral sclerosis: a european population-based case-control study from the EURALS consortium. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 118-125.	1.1	26
53	Reduced mitochondrial D-loop methylation levels in sporadic amyotrophic lateral sclerosis. Clinical Epigenetics, 2020, 12, 137.	1.8	26
54	Neurofilament light chain and C reactive protein explored as predictors of survival in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 436-437.	0.9	25

#	Article	IF	Citations
55	Unraveling gene expression profiles in peripheral motor nerve from amyotrophic lateral sclerosis patients: insights into pathogenesis. Scientific Reports, 2016, 6, 39297.	1.6	24
56	BDNF Serum Levels with Respect to Multidimensional Assessment in Amyotrophic Lateral Sclerosis. Neurodegenerative Diseases, 2016, 16, 192-198.	0.8	24
57	Blood trace metals in a sporadic amyotrophic lateral sclerosis geographical cluster. BioMetals, 2017, 30, 355-365.	1.8	24
58	The cognitive and behavioural profile of amyotrophic lateral sclerosis: application of the consensus criteria. Behavioural Neurology, 2013, 27, 143-53.	1.1	24
59	Novel <scp>FUS</scp> mutations identified through molecular screening in a large cohort of familial and sporadic amyotrophic lateral sclerosis. European Journal of Neurology, 2015, 22, 1474-1481.	1.7	23
60	Amyotrophic Lateral Sclerosis Survival Score (ALS-SS): A simple scoring system for early prediction of patient survival. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 93-100.	1.1	23
61	HSC70 expression is reduced in lymphomonocytes of sporadic ALS patients and contributes to TDP-43 accumulation. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 51-62.	1.1	22
62	Phosphorylated TDP-43 aggregates in peripheral motor nerves of patients with amyotrophic lateral sclerosis. Brain, 2022, 145, 276-284.	3.7	22
63	The experience of meditation for people with amyotrophic lateral sclerosis and their caregivers â€“ a qualitative analysis. Psychology, Health and Medicine, 2016, 21, 762-768.	1.3	21
64	Coexistence of variants in TBK1 and in other ALS-related genes elucidates an oligogenic model of pathogenesis in sporadic ALS. Neurobiology of Aging, 2019, 84, 239.e9-239.e14.	1.5	21
65	Phenotypic Heterogeneity in a SOD1 G93D Italian ALS Family: An Example of Human Model to Study a Complex Disease. Journal of Molecular Neuroscience, 2011, 44, 25-30.	1.1	20
66	Behavioural But Not Cognitive Impairment Is a Determinant of Caregiver Burden in Amyotrophic Lateral Sclerosis. European Neurology, 2016, 75, 191-194.	0.6	20
67	Serum irisin is upregulated in patients affected by amyotrophic lateral sclerosis and correlates with functional and metabolic status. Journal of Neurology, 2018, 265, 3001-3008.	1.8	20
68	Free insulinâ€like growth factor (IGF)â€1 and IGFâ€binding proteinsâ€2 and â€3 in serum and cerebrospinal fluid of amyotrophic lateral sclerosis patients. European Journal of Neurology, 2010, 17, 398-404.	1.7	19
69	ATXN2 is a modifier of phenotype in ALS patients of Sardinian ancestry. Neurobiology of Aging, 2015, 36, 2906.e1-2906.e5.	1.5	19
70	Comorbidity of dementia with amyotrophic lateral sclerosis (ALS): insights from a large multicenter Italian cohort. Journal of Neurology, 2017, 264, 2224-2231.	1.8	19
71	The prognostic value of spirometric tests in Amyotrophic Lateral Sclerosis patients. Clinical Neurology and Neurosurgery, 2019, 184, 105456.	0.6	19
72	Diagnostic and prognostic values of PBMC proteins in amyotrophic lateral sclerosis. Neurobiology of Disease, 2020, 139, 104815.	2.1	19

#	Article	IF	Citations
73	Decoding distinctive features of plasma extracellular vesicles in amyotrophic lateral sclerosis. Molecular Neurodegeneration, 2021, 16, 52.	4.4	19
74	Microstructural Correlates of Emotional Attribution Impairment in Non-Demented Patients with Amyotrophic Lateral Sclerosis. PLoS ONE, 2016, 11, e0161034.	1.1	19
75	Lack of association of PON polymorphisms with sporadic ALS in an Italian population. Neurobiology of Aging, 2011, 32, 552.e7-552.e13.	1.5	18
76	MEF2D and MEF2C pathways disruption in sporadic and familial ALS patients. Molecular and Cellular Neurosciences, 2016, 74, 10-17.	1.0	18
77	Collagen XIX Alpha 1 Improves Prognosis in Amyotrophic Lateral Sclerosis. , 2019, 10, 278.		18
78	Intrathecal nusinersen treatment for SMA in a dedicated neuromuscular clinic: an example of multidisciplinary and integrated care. Neurological Sciences, 2019, 40, 327-332.	0.9	18
79	ALS Cognitive Behavioral Screen (ALS-CBS): normative values for the Italian population and clinical usability. Neurological Sciences, 2020, 41, 835-841.	0.9	18
80	Primitive reflexes in amyotrophic lateral sclerosis: prevalence and correlates. Journal of Neurology, 2014, 261, 1196-1202.	1.8	17
81	Meditation Training for People with Amyotrophic Lateral Sclerosis and Their Caregivers. Journal of Alternative and Complementary Medicine, 2014, 20, 272-275.	2.1	16
82	Taste changes in amyotrophic lateral sclerosis and effects on quality of life. Neurological Sciences, 2019, 40, 399-404.	0.9	16
83	Tear-Based Vibrational Spectroscopy Applied to Amyotrophic Lateral Sclerosis. Analytical Chemistry, 2021, 93, 16995-17002.	3.2	16
84	Respiratory function of people with amyotrophic lateral sclerosis and caregiver distress level: a correlational study. BioPsychoSocial Medicine, 2012, 6, 14.	0.9	15
85	Multimodal MRI quantification of the common neurostructural bases within the FTD-ALS continuum. Neurobiology of Aging, 2018, 62, 95-104.	1.5	15
86	Sport activity in Charcotâ€“Marieâ€“Tooth disease: A case study of a Paralympic swimmer. Neuromuscular Disorders, 2016, 26, 614-618.	0.3	14
87	Protein misfolding, amyotrophic lateral sclerosis and guanabenz: protocol for a phase II RCT with futility design (ProMISe trial). BMJ Open, 2017, 7, e015434.	0.8	14
88	Anxiety and Depression in Patients with Amyotrophic Lateral Sclerosis and Their Caregivers. Current Psychology, 2012, 31, 79-87.	1.7	13
89	Grey matter damage in progressive multiple sclerosis versus amyotrophic lateral sclerosis: a voxel-based morphometry MRI study. Neurological Sciences, 2015, 36, 371-377.	0.9	13
90	Irisin and BDNF serum levels and behavioral disturbances in Alzheimerâ€™s disease. Neurological Sciences, 2019, 40, 1145-1150.	0.9	13

#	Article	IF	Citations
91	Which are the factors influencing NIV adaptation and tolerance in ALS patients?. Neurological Sciences, 2021, 42, 1023-1029.	0.9	13
92	Aggressiveness, sexuality, and obsessiveness in late stages of ALS patients and their effects on caregivers. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 452-458.	2.3	12
93	Brain MRI shows white matter sparing in Kennedy's disease and slowâ€progressing lower motor neuron disease. Human Brain Mapping, 2019, 40, 3102-3112.	1.9	12
94	Clinical psychology and amyotrophic lateral sclerosis. Frontiers in Psychology, 2010, 1, 33.	1.1	11
95	Burden of Rare Variants in ALS and Axonal Hereditary Neuropathy Genes Influence Survival in ALS: Insights from a Next Generation Sequencing Study of an Italian ALS Cohort. International Journal of Molecular Sciences, 2020, 21, 3346.	1.8	11
96	The hypometabolic state: a good predictor of a better prognosis in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 41-47.	0.9	11
97	Association of Clinically Evident Eye Movement Abnormalities With Motor and Cognitive Features in Patients With Motor Neuron Disorders. Neurology, 2021, 97, e1835-e1846.	1.5	11
98	Amyotrophic lateral sclerosis in pregnancy is associated with a vascular endothelial growth factor promoter genotype. European Journal of Neurology, 2014, 21, 594-598.	1.7	10
99	Osteopathic Manual Treatment for Amyotrophic Lateral Sclerosis: A Feasibility Pilot Study. The Open Neurology Journal, 2016, 10, 59-66.	0.4	10
100	Emerging Drugs for the Treatment of Amyotrophic Lateral Sclerosis: A Focus on Recent Phase 2 Trials. Expert Opinion on Emerging Drugs, 2020, 25, 145-164.	1.0	10
101	Urinary neopterin, a new marker of the neuroinflammatory status in amyotrophic lateral sclerosis. Journal of Neurology, 2020, 267, 3609-3616.	1.8	10
102	Non-self-sufficiency as a primary outcome measure in ALS trials. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 77-84.	1.1	9
103	Screening for early symptoms of respiratory involvement in myotonic dystrophy type 1 using the Respicheck questionnaire. Neuromuscular Disorders, 2020, 30, 301-309.	0.3	9
104	Plasma amino acids patterns and age of onset of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2014, 15, 371-375.	1.1	8
105	HFE p.H63D polymorphism does not influence ALS phenotype and survival. Neurobiology of Aging, 2015, 36, 2906.e7-2906.e11.	1.5	8
106	Serum Proteome in a Sporadic Amyotrophic Lateral Sclerosis Geographical Cluster. Proteomics - Clinical Applications, 2017, 11, 1700043.	0.8	8
107	Replication of association of CHRNA4 rare variants with sporadic amyotrophic lateral sclerosis: The Italian multicentre study. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 580-584.	2.3	7
108	G-CSF (filgrastim) treatment for amyotrophic lateral sclerosis: protocol for a phase II randomised, double-blind, placebo-controlled, parallel group, multicentre clinical study (STEMALS-II trial). BMJ Open, 2020, 10, e034049.	0.8	7

#	Article	IF	Citations
109	The heterozygous deletion c.1509_1510delAG in exon 14 of FUS causes an aggressive childhood-onset ALS with cognitive impairment. Neurobiology of Aging, 2021, 103, 130.e1-130.e7.	1.5	7
110	ATNX2 is not a regulatory gene in Italian amyotrophic lateral sclerosis patients with C9ORF72 GGGGCC expansion. Neurobiology of Aging, 2016, 39, 218.e5-218.e8.	1.5	6
111	The development of an augmented reality device for the autonomous management of the electric bed and the electric wheelchair for patients with amyotrophic lateral sclerosis: a pilot study. Disability and Rehabilitation: Assistive Technology, 2021, 16, 513-519.	1.3	6
112	Ocular Involvement Occurs Frequently at All Stages of Amyotrophic Lateral Sclerosis: Preliminary		